Optipharm.CO.,LTD Logo

Optipharm.CO.,LTD

Biotech for animal health and xenotransplantation using genetically engineered pig organs.

153710 | KO

Overview

Corporate Details

ISIN(s):
KR7153710009
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 오송생명6로 63, 청주시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Optipharm.CO.,LTD is a biotechnology company specializing in animal health and advanced biomedical solutions. The company's core activities include animal disease diagnosis, the development of veterinary pharmaceuticals, bacteriophage-based products, and Virus-Like Particle (VLP) vaccines. A key focus for Optipharm is xenotransplantation, where it conducts pioneering research and development of genetically engineered pigs for organ transplantation to address human organ shortages. The company has achieved significant milestones in preclinical trials, including record survival times for primates that have received transplanted organs, positioning it at the forefront of regenerative medicine and organ transplant technology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-03 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-07-31 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.8 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.4 KB
2025-06-10 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-05-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-05-02 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (민군겸용 기술개발사업(형질전환돼지 기반 수혈가능 이종적혈구제제 기술개발) 국책과제 …
Korean 23.4 KB
2025-04-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.6 KB
2025-03-24 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.2 KB
2025-03-20 00:00
Regulatory News Service
[기재정정]신규시설투자등
Korean 11.4 KB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 17.7 KB
2025-03-14 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.5 MB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.6 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 154.7 KB

Automate Your Workflow. Get a real-time feed of all Optipharm.CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Optipharm.CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Optipharm.CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Atomera Inc Logo
Licenses semiconductor material and IP to enhance transistor performance and power efficiency.
United States of America
ATOM
Atrae, Inc. Logo
Develops People Tech solutions for HR, including big data job sites and organizational analytics.
Japan
6194
Developing uranium and battery minerals for the nuclear energy and energy storage markets.
Australia
AEE
Avalo Therapeutics, Inc. Logo
Clinical-stage biotech developing IL-1β therapies for immune inflammatory diseases.
United States of America
AVTX
AVIS BUDGET GROUP, INC. Logo
Global provider of car rental, truck rental, and car-sharing for business & leisure travelers.
United States of America
CAR
Azenta, Inc. Logo
Life science solutions for pharma & biotech, offering sample management, storage & multiomics.
United States of America
AZTA
BayCurrent, Inc. Logo
Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.
Japan
6532
BenevolentAI Logo
An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.
United Kingdom
BAI
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway
BGBIO
Bergman & Beving Logo
Acquires and develops niche companies with solutions for the industrial and construction sectors.
Sweden
BERG

Talk to a Data Expert

Have a question? We'll get back to you promptly.